We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serological Assays Assessed for Q Fever

By LabMedica International staff writers
Posted on 24 Oct 2012
A quality assessment was performed for three different serological methods that are routinely used in the diagnosis of Q fever. More...


The indirect immunofluorescence assay (IFA) is considered the reference method for diagnosing Q fever, but serology is also performed by complement fixation assay (CFA) or enzyme-linked immunosorbent assay (ELISA), however, comparability between these assays is not clear.

A total of 13 laboratories collaborated in multi-institution study to test the various methods and the results were collated by the Center for Infectious Disease Control, (RIVM; Bilthoven, The Netherlands). The Q fever cases were confirmed either by a positive polymerase chain reaction (PCR) or by seroconversion. In total, the proficiency panel consisted of 25 serum samples: five samples with an intended negative outcome, six samples from acute Q fever patients, and eight serially diluted high-positive sample from a Q fever patient.

The five Dutch laboratories that performed IFA all used the same commercially available IFA (Focus Diagnostics, Cypress, CA, USA). Six laboratories carried out a commercially available CFA (Virion-Serion; Würzburg, Germany), and five participants also performed the Virion-Serion's ELISA and one laboratory used an ELISA from Inverness Medical Innovations, (Waltham, MA, USA). Three national reference laboratories from outside the Netherlands also participated and all used an in-house IFA.

For the diagnosis of Q fever, all assays reached a specificity of 95% to 100% in the samples with an intended negative outcome. All laboratories correctly identified Q fever patients with the algorithm of the methods that were applied. The IFA, ELISA, and CFA values between laboratories using the same methods were within close range, with usually no more than two dilution differences in the reported titer. However, there were differences in sensitivity between the methods.

The IFA proved to be the most sensitive assay in detecting a past Q fever infection. All laboratories using IFA detected both immunoglobulin G (IgG) phase I antibodies (titers ranged from 1:32 to1:256) and phase II antibodies (titers ranged from1:128 to 1:512) in samples in these patients. The ELISA yielded mostly intermediate IgG phase II responses, and four of six laboratories using CFA detected only low titers of 1:10 to1:20 against phase II. No IgM response was detected with any of the applied assays.

Q fever is a highly contagious zoonotic disease caused by Coxiella burnetii, a Gram-negative obligate intracellular bacterium. Since 2007, the Netherlands has been faced with the largest outbreak of Q fever ever reported, with over 4,000 notified cases. The authors concluded that IFA, ELISA, and CFA are all suitable serodiagnostic assays for diagnosing acute Q fever. ELISAs can be an alternative for screening large sample numbers. The IFA appears to be the method of choice when high sensitivity is required, especially against phase I, and for example identifying chronic Q fever. The study was published on October 5, 2012, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Netherlands Center for Infectious Disease Control
Focus Diagnostics
Virion-Serion



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Fusun Can (at left) is developing a test for detecting both resistance and virulence in Klebsiella pneumoniae (Photo courtesy of Koç University)

Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae

Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.